Clearside Biomedical (NASDAQ:CLSD) has entered into a strategic collaboration with EyeKor to support Clearside’s ophthalmic clinical trial activities.
Clearside is currently conducting Phase 3 clinical trials of suprachoroidally administered CLS-TA, its suspension formulation of the corticosteroid, triamcinolone acetonide, in patients with macular edema associated with non-infectious uveitis, as well as suprachoroidal CLS-TA used concomitantly with intravitreally administered EYLEA in patients with macular edema associated with retinal vein occlusion (RVO). Clearside also has a clinical program in diabetic macular edema.
EyeKor is a software-as-a-service company providing image and data management solutions for ophthalmic clinical trials. As part of the collaboration, Clearside will use Excelsior, EyeKor’s 510(k)-cleared, cloud-based software platform, for both clinical and preclinical applications.
The software platform will enable Clearside and its contract research organization (CRO) partners to manage the ocular images and other data collected during its ophthalmic clinical trials and nonclinical studies, enhancing the efficiency and accuracy of data collection and potential interpretation.
It will also allow leading scientists, principal investigators, CRO representatives, data managers and reading center graders to access and track data in real time.
“EyeKor did an outstanding job in our two completed Phase 2 trials in uveitis and in RVO, and is continuing to support our clinical research programs,” Daniel White, president and CEO of Clearside, said in a statement.
“The level of service and the prompt and thoughtful nature of their assistance, coupled with the powerful and efficient Excelsior platform, is not just greatly appreciated, but also highly valued,” he added.
Christopher Murphy, CEO of EyeKor, said the strategic collaboration with Clearside is an important step for EyeKor to validate the “great power of our Excelsior application, by assisting Clearside in bringing its ophthalmic therapeutics into the marketplace to benefit patients suffering from serious back-of-the-eye diseases.”